STLP1 Antibody

What is StIP1 and what cellular functions does it regulate?

StIP1 (Stress-induced phosphoprotein-1) plays a crucial role in regulating signal transducer and activator of transcription 3 (Stat3), which is involved in numerous biological processes including nephrogenesis, gliogenesis, hepatogenesis, T cell proliferation, inflammation, and oncogenesis. StIP1 contains 12 WD40 repeats that facilitate protein-protein interactions, particularly with members of the c-Jun N-terminal kinase (JNK) family. It functions as a scaffold protein, enhancing interaction between JNK and Stat3, thereby influencing Stat3 activation and subsequent nuclear translocation . Research has shown that overexpression of StIP1 inhibits Stat3 activation and Stat3-dependent induction of reporter genes, indicating its potential role in modulating cytokine signaling pathways. Additionally, StIP1 maintains the stability of JAK2 in various cellular contexts .

What detection methods are compatible with StIP1 antibodies?

The StIP1 Antibody (C-5) mouse monoclonal IgG2b kappa light chain antibody can detect StIP1 protein of mouse origin using multiple detection methods including:

• Western blotting (WB)

• Immunoprecipitation (IP)

• Immunofluorescence (IF)

• Enzyme-linked immunosorbent assay (ELISA)

Additionally, this antibody is available in multiple formats to support various experimental approaches:

How can I optimize western blotting protocols for StIP1 detection?

For optimal western blotting results with StIP1 antibody:

• Sample preparation: Use RIPA buffer supplemented with protease inhibitors to extract total protein from cells or tissues.

• Protein loading: Load 20-40 μg of total protein per lane.

• Gel concentration: Use 10% SDS-PAGE for optimal resolution of StIP1 (molecular weight approximately 63 kDa).

• Transfer conditions: Transfer to PVDF membrane at 100V for 1 hour using standard Tris-glycine buffer.

• Blocking: Block with 5% non-fat dry milk in TBST for 1 hour at room temperature.

• Primary antibody: Dilute StIP1 Antibody (C-5) at 1:1000 in blocking buffer and incubate overnight at 4°C.

• Secondary antibody: For non-conjugated primary antibody, use anti-mouse IgG-HRP at 1:5000 dilution for 1 hour at room temperature.

• Detection: Use enhanced chemiluminescence (ECL) detection reagents and expose to X-ray film or digital imager.

If signal-to-noise ratio is suboptimal, consider using the HRP-conjugated version (sc-393475 HRP) to eliminate background from secondary antibodies .

How can I utilize StIP1 antibodies to investigate JAK-STAT signaling pathways?

StIP1 plays a significant role in JAK-STAT signaling by maintaining JAK2 stability and regulating Stat3 activation. To investigate these interactions:

• Co-immunoprecipitation: Use StIP1 Antibody (C-5) AC (agarose-conjugated) to pull down StIP1 protein complexes and analyze associated proteins (JAK2, Stat3) by western blotting.

• Sequential immunoprecipitation: First immunoprecipitate with anti-JAK2 antibody, then perform western blotting with StIP1 antibody to confirm interaction.

• Proximity ligation assay (PLA): Use StIP1 antibody in combination with anti-JAK2 or anti-Stat3 antibodies to visualize protein-protein interactions in situ with subcellular resolution.

• Chromatin immunoprecipitation (ChIP): After stimulation with cytokines that activate JAK-STAT pathway, use StIP1 antibody to evaluate its presence at genomic regions where Stat3 binds.

• Signal inhibition analysis: Compare phosphorylation status of JAK2 and Stat3 in control cells versus cells with StIP1 knockdown using phospho-specific antibodies in parallel with StIP1 antibody detection.

These approaches allow researchers to map the precise interactions and functional consequences of StIP1 in JAK-STAT signaling cascades under various physiological and pathological conditions .

What are the considerations when designing StIP1 knockout/knockdown validation experiments?

When validating StIP1 antibody specificity through knockout or knockdown approaches:

• Multiple silencing strategies: Employ both siRNA (transient) and shRNA (stable) approaches targeting different regions of StIP1 mRNA to rule out off-target effects.

• Rescue experiments: After StIP1 knockdown, re-express siRNA-resistant StIP1 construct to confirm phenotype reversal.

• CRISPR/Cas9 validation: Create complete StIP1 knockout cell lines and confirm absence of signal with StIP1 antibody across multiple detection methods.

• Dose-dependent validation: Show gradual reduction in StIP1 signal with increasing concentrations of siRNA or shRNA.

• Documentation requirements:

  • Include both positive and negative controls in all validation experiments

  • Provide quantification of knockdown efficiency (qPCR and western blot)

  • Document all bands detected by the antibody, not just the target band

  • Validate in multiple cell types where possible

These rigorous validation protocols ensure that experimental outcomes attributed to StIP1 manipulation are specific and reproducible across research conditions .

How do post-translational modifications affect StIP1 antibody recognition?

StIP1 undergoes various post-translational modifications that can affect antibody recognition:

• Phosphorylation: As a stress-induced phosphoprotein, StIP1 phosphorylation status changes under different cellular conditions. The StIP1 Antibody (C-5) recognizes the protein regardless of phosphorylation state, but phospho-specific antibodies would be required to distinguish activation states.

• Ubiquitination: This modification may mask epitopes recognized by some antibodies. When studying StIP1 degradation pathways, treat samples with deubiquitinating enzymes before immunoblotting to improve detection.

• Methodology for assessing modification impact:

  • Treat cell lysates with phosphatases or kinases before immunoblotting

  • Compare antibody detection in stress-induced versus normal conditions

  • Use immunoprecipitation followed by mass spectrometry to identify specific modified residues

  • Compare detection patterns across multiple StIP1 antibodies recognizing different epitopes

Understanding these modifications is crucial when interpreting experimental results, particularly in studies examining StIP1's role in stress responses and protein quality control mechanisms .

What are common causes of false positive or false negative results with StIP1 antibodies?

False positive results may occur due to:

• Cross-reactivity with structurally similar proteins, especially other WD40 repeat-containing proteins

• Non-specific binding to Fc receptors in immune cells

• Excessive antibody concentration leading to background signal

• Inadequate blocking or washing steps in immunoassays

False negative results may occur due to:

• Epitope masking by protein-protein interactions, particularly with JNK family members

• Sample preparation methods that denature the epitope recognized by the antibody

• Low expression levels of StIP1 in certain cell types or conditions

• Interfering post-translational modifications at the antibody binding site

Mitigation strategies include:

• Validate antibody specificity using multiple detection methods

• Include appropriate positive and negative controls

• Optimize antibody concentration through titration experiments

• Consider native versus denaturing conditions based on experimental goals

• Use multiple antibodies targeting different epitopes to confirm results

How can I optimize immunofluorescence protocols for StIP1 localization studies?

For optimal subcellular localization studies of StIP1:

• Fixation method comparison:

  • 4% paraformaldehyde (10 minutes) preserves protein-protein interactions

  • Methanol:acetone (1:1, -20°C, 10 minutes) enhances nuclear epitope accessibility

  • Compare both methods to determine optimal epitope exposure

• Permeabilization optimization:

  • 0.1% Triton X-100 for standard permeabilization

  • 0.5% saponin for gentler permeabilization that better preserves membrane structures

  • Digitonin (50 μg/ml) for selective plasma membrane permeabilization

• Antibody dilution: Start with 1:100 dilution and optimize based on signal-to-noise ratio

• Signal amplification: Consider using fluorophore-conjugated secondary antibodies with high quantum yield or tyramide signal amplification for low-abundance targets

• Counterstaining recommendations:

  • DAPI for nuclear visualization

  • Phalloidin for F-actin/cytoskeletal context

  • Specific organelle markers (mitochondria, ER, Golgi) to assess colocalization

• Controls for specificity:

  • StIP1 knockdown cells as negative control

  • Peptide competition assay

  • Secondary-only control for background assessment

These optimizations will help visualize StIP1's dynamic localization between cytoplasmic and nuclear compartments, particularly following stress induction or cytokine stimulation .

How does StIP1 expression vary across different experimental models and disease states?

StIP1 expression patterns vary significantly across experimental models and disease conditions:

• Cell line variations:

  • Highest expression in hepatocytes, neuronal cells, and immune cells

  • Lower expression in fibroblasts and epithelial cells

  • Inducible expression following stress conditions (heat shock, oxidative stress)

• Disease-specific alterations:

  • Upregulated in inflammatory conditions through JAK-STAT pathway activation

  • Altered in neurodegenerative disorders involving protein misfolding

  • Dysregulated in certain cancers where STAT3 signaling is constitutively active

• Model-specific considerations:

  • Mouse models show developmental regulation of StIP1 expression

  • Primary cells may exhibit different baseline expression than immortalized lines

  • Patient-derived samples show heterogeneous expression based on disease stage

When designing experiments, researchers should first establish baseline StIP1 expression in their model system using the StIP1 antibody, then consider how experimental manipulations or disease conditions might alter this expression profile. This characterization is essential for proper interpretation of functional studies targeting StIP1 and its associated signaling pathways .

What methodological approaches can validate StIP1 antibody specificity across species?

To validate StIP1 antibody cross-reactivity and specificity across species:

• Sequence homology analysis:

  • Perform sequence alignment of the epitope region recognized by StIP1 Antibody (C-5) across species

  • Predict potential cross-reactivity based on epitope conservation

• Experimental validation approaches:

  • Western blot analysis using recombinant StIP1 proteins from different species

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

  • Side-by-side comparison using samples from multiple species at equivalent protein concentrations

• Knockout/knockdown validation:

  • Test antibody on samples from StIP1 knockout mice

  • Use siRNA in cells from different species to confirm signal reduction

• Peptide competition assay:

  • Pre-incubate antibody with blocking peptides derived from StIP1 sequences of different species

  • Observe species-specific blocking of antibody binding

• Documentation requirements:

  • Species-specific positive controls

  • Detailed recording of any cross-reactive bands

  • Molecular weight variations across species

While the StIP1 Antibody (C-5) is specified for mouse StIP1 detection, proper validation may reveal utility in other species due to conserved epitopes. Researchers should conduct these validation steps before extending use to non-mouse models .

How can I quantitatively analyze StIP1-Stat3 interactions in different cellular compartments?

Quantitative analysis of StIP1-Stat3 interactions requires multimodal approaches:

• Subcellular fractionation protocol:

  • Separate nuclear, cytoplasmic, and membrane fractions using differential centrifugation

  • Validate fraction purity using compartment-specific markers (GAPDH, Lamin B1, Na+/K+-ATPase)

  • Quantify StIP1 and Stat3 in each fraction by western blotting

• Co-immunoprecipitation quantification:

  • Use StIP1 Antibody (C-5) AC for immunoprecipitation from different cellular compartments

  • Measure Stat3 co-precipitation by western blot densitometry

  • Calculate interaction efficiency as ratio of precipitated Stat3 to total Stat3 input

• Advanced imaging analysis:

  • Perform confocal microscopy with StIP1 and Stat3 antibodies

  • Quantify colocalization using Pearson's correlation coefficient or Manders' overlap coefficient

  • Use FRET or BRET approaches for direct interaction measurement

• Dynamic interaction analysis:

  • Track StIP1-Stat3 interactions after cytokine stimulation using time-course immunoprecipitation

  • Measure nuclear translocation kinetics of both proteins

• Data presentation:

  • Report colocalization coefficients with statistical analysis

  • Present compartment-specific interaction data in normalized formats

  • Include time-course data to capture dynamic regulation

These approaches allow researchers to move beyond qualitative observations to precise quantification of StIP1-Stat3 interactions in different subcellular contexts and under varying experimental conditions .

What statistical approaches are recommended for analyzing variable StIP1 expression data across experimental replicates?

When analyzing StIP1 expression data with inherent biological variability:

• Normalization strategies:

  • Normalize StIP1 expression to stable housekeeping proteins (β-actin, GAPDH, tubulin)

  • Consider using multiple reference proteins and geometric averaging for more robust normalization

  • For tissue samples, normalize to total protein using stain-free technology or Ponceau staining

• Statistical methods for western blot densitometry:

  • Minimum of three biological replicates (different passages or individuals)

  • Use non-parametric tests (Mann-Whitney U) for small sample sizes

  • Apply ANOVA with appropriate post-hoc tests for multiple comparisons

  • Report standard error of mean (SEM) or 95% confidence intervals

• Handling outliers:

  • Define outlier criteria before analysis (e.g., >2 standard deviations from mean)

  • Document all excluded data points with rationale

  • Consider robust statistical methods less sensitive to outliers

• Power analysis:

  • Calculate required sample size based on expected effect size and variability

  • Report power calculations in methods section

• Data presentation recommendations:

  • Include representative blot images alongside quantification graphs

  • Normalize to control condition (set as 1.0 or 100%) for fold-change presentation

  • Consider box plots or violin plots instead of bar graphs to show data distribution

These approaches enhance reproducibility and statistical rigor when analyzing StIP1 expression data across different experimental conditions and models .

How can StIP1 antibodies be integrated into high-throughput screening workflows?

StIP1 antibodies can be incorporated into high-throughput screening approaches through:

• Automated immunoassay platforms:

  • Adapt StIP1 ELISA protocols for 384-well format

  • Develop homogeneous assays (no-wash formats) using HTRF or AlphaLISA technologies

  • Create bead-based multiplexed assays to measure StIP1 alongside interacting partners

• High-content imaging applications:

  • Optimize immunofluorescence protocols for automated microscopy

  • Develop image analysis algorithms to quantify StIP1 expression, localization, and colocalization

  • Implement machine learning for pattern recognition in StIP1 distribution

• Functional screening integration:

  • Combine with CRISPR libraries targeting StIP1 interactors

  • Screen for compounds that modulate StIP1-dependent signaling

  • Develop reporter cell lines where StIP1 activity correlates with fluorescent/luminescent readout

• Quality control considerations:

  • Include internal standards across plates for normalization

  • Implement Z-factor analysis to ensure assay robustness

  • Validate hits with orthogonal, low-throughput methods

These approaches enable screening of larger compound libraries or genetic perturbations for effects on StIP1-mediated cellular processes, particularly in contexts relevant to inflammation and cancer research .

What emerging technologies might enhance StIP1 antibody-based research?

Several cutting-edge technologies show promise for advancing StIP1 antibody applications:

• Single-cell proteomics:

  • Adapting StIP1 antibodies for mass cytometry (CyTOF)

  • Developing proximity extension assays for single-cell protein interaction analysis

  • Integration with single-cell transcriptomics for multi-omic analysis

• Super-resolution microscopy applications:

  • Optimizing StIP1 antibodies for STORM, PALM, or STED microscopy

  • Visualizing nanoscale StIP1 protein complexes and their dynamic assembly

  • Combining with expansion microscopy for enhanced spatial resolution

• In situ protein analysis:

  • Adapting StIP1 antibodies for Nanostring digital spatial profiling

  • Developing multiplex immunofluorescence panels including StIP1

  • Optimizing for CODEX or 4i iterative immunofluorescence techniques

• Live-cell applications:

  • Developing cell-permeable StIP1 antibody fragments

  • Creating intrabodies for real-time monitoring of StIP1 in living cells

  • Combining with optogenetic approaches to manipulate StIP1 interactions

• Structural biology integration:

  • Using antibodies to stabilize StIP1 conformations for cryo-EM analysis

  • Developing antibodies specific to different conformational states

These emerging technologies will enable researchers to study StIP1 with unprecedented spatial and temporal resolution, providing deeper insights into its role in cellular signaling networks and disease mechanisms .